- Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin
and soft tissue infections caused by methicillin-resistantStaphylococcus aureus. Antimicrob Agents
Chemother 2007; 51:3298–3303. - Patanwala AE, Erstad BL, Nix DE. Cost-effectiveness of linezolid and vancomycin in the treatment of
surgical site infections. Curr Med Res Opin 2007; 23:185–193. - Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against
strains of methicillin-resistantStaphylococcus aureus with reduced vancomycin susceptibility in
diabetic patients with foot infections. J Antimicrob Chemother 2007; 60:819–823. - Vercillo M, Patzakis MJ, Holtom P, et al. Linezolid in the treatment of implant-related chronic
osteomyelitis. Clin Orthop Relat Res 2007; 461:40–43. - Kallweit U, Harzheim M, Marklein G, et al. Successful treatment of methicillin-resistantStaphylococcus
aureusmeningitis using linezolid without removal of intrathecal infusion pump. Case report.
J Neurosurg 2007; 107:651–653. - Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistantStaphylococcus aureus
with linezolid. Infection 2007; 35:271–274. - Hackbarth CJ, Chamberg HF, Sande MA. Serum bactericial acitivity of rifampin in combination
with other antimicrobial agents againstStaphylococcus aureus.Antimicrob Agents Chemother 1986;
29:611–613. - Dombrowski JC, Winston LG. Clinical failures of appropriately-treated methicillin-resistant
Staphylococcus aureusinfections. J Infect 2008; 57:110–115. - Lodise TP, Graves J, Evans A, et al. Relationship between vancomcyin MIC and failure among
patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.
Antimicrob Agents Chemother 2008; 52:3315–3320. - Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration
on the treatment of methicillin-resistant Staphylococcus aureusbacteremia. Clin Infect Dis 2008;
46:193–200. - Cui L, Ma K, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in
Staphylococcus aureus. J Clin Microbiol 2003; 41:5–14. - Moise PA, Smyth DS, El-Fawal N, et al. Microbiological effects of prior vancomycin use in patients
with methicillin-resistantStaphylococcus aureusbacteremia. J Antimicrob Chemother 2008; 61:85–90. - Charles PGP, Ward PB, Johnson PDR, et al. Clinical features associated with bacteremia due to
heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448–451. - Bennett JW, Murray CK, Holmes RL, et al. Diminished vancomycin and daptomycin susceptibility
during prolonged bacteremia with methicillin-resistantStaphylococcus aureus. Diagn Microbiol Infect
Dis 2008; 60:437–440. - Cunha BA. Vancomycin revisisted: a reapprasal of clinical use. Crit Care Clin 2008; 24:394–420.
- Huang YT, Hsiao CH, Liao CH, et al. Bacteremia and infective endocarditis caused by a non-
daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus
strain in Taiwan. J Clin Microbiol 2008; 46:1132–1136. - Weis F, Beiras-Fernandez A, Kaczmarek I, et al. Daptomycin for eradication of a systemic infection
with a methicillin-resistant -Staphylococcus aureus in a biventricular assist device recipient. Ann
Thorac Surg 2007; 84:269–270. - Saribas S, Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy 2004; 50:250–254.
- Watanakunakorn C. Antibiotic-tolerant Staphylococcus aureus. J Antimicrob Chemother 1978;
4:561–568. - Cunha BA, Mikhail N, Eisenstein L. Persistent methicillin resistant bacteremia S. aureus (MRSA) due
to linezolid “tolerant strain”. Heart Lung 2008; 37:398–400. - Cunha BA, Ortega A. Antibiotic failure. Med Clin North Am 1995; 79:663–672.
- Schwartz BS, Graber CJ, Diep BA, et al. Doxycycline, not minocycline, induces its own Resistance in
multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone
USA300. Clin Infect Dis 2009; 48:1483–1484.
Antimicrobial Therapy of VRE and MRSA in Critical Care 511